Efficacy and Safety of Danshen Compound Tablets in Preventing Thalidomide-Associated Thromboembolism in Patients with Multiple Myeloma: A Multicenter Retrospective Study

Qing-song Yin, Lin Chen, Rui-hua Mi, Hao Ai, Jun-jie Yin, Xiao-juan Liu, Xu-dong Wei

Background: Currently available antithrombotic prophylaxis is not perfectly reliable in elderly patients. The aim of this retrospective study was to evaluate the efficacy and safety of Compound Danshen Tablet (CDT) in preventing thromboembolism in multiple myeloma (MM) patients treated with thalidomide-based regimens.

Material/Methods: MM patients treated with thalidomide-based regimens were retrospectively reviewed between January 2008 and March 2015. Patients were categorized into 3 cohorts based on thromboembolic prophylaxis used: CDT, Warfarin Tablet, and no prophylaxis. Venous thromboembolism (VTE), other adverse effects (AEs), and the changes of D-dimer and fibrinogen levels were monitored.

Results: Seven out of 313 MM patients (2.24%) developed venous thrombosis events (VTE) in this retrospective study, all clustering in the no prophylaxis cohort. Three patients of the Warfarin cohort (3.19%) experienced hemorrhage. Neither VTE events nor serious AEs were observed in the CDT cohort. Following Compound Danshen or Warfarin treatment for 3 months, the D-dimer and fibrinogen levels (in particular the D-dimer level) (all \( P < 0.05 \)), were obviously decreased relative to their respective baselines and the no prophylaxis cohort. In contrast, the 2 blotting parameters were significantly increased in the no prophylaxis cohort relative to the baseline level (All \( P < 0.05 \)), and were even higher in the patients experiencing VTE compared to the no VTE patients (\( P < 0.0001 \) and \( P = 0.016 \), respectively).

Conclusions: Our findings indicate CDT is an effective therapy for preventing VTE in MM patients treated with thalidomide-based regimens, and is well tolerated in long-term use.

MeSH Keywords: Multiple Myeloma • Thalidomide • Venous Thrombosis

Corresponding Author: Xudong Wei, e-mail: xudongwei@zzu.edu.cn

Source of support: The National Natural Science Foundation of China (No. 81000921) and the Natural Science Foundation of Henan Province (No. 201204109)
Background

Multiple myeloma (MM) is a plasma cell neoplasm characterized by the presence of monoclonal immunoglobulin in the serum and/or urine and clinical symptoms related to end-organ damage comprising hypercalcemia, renal insufficiency, anemia, and bone complications (CRAB features) [1]. MM accounts for approximately 1% of all types of cancer and 13% of hematologic malignancies, and primarily affects the elderly, with a median age at diagnosis of about 70 years [2]. The prognosis of MM is heterogeneous due to patient-related risk factors such as age and comorbidity, as well as disease-related risk factors such as stage and cytogenetic abnormality [1]. In the last decade, the outcome of MM patients has been significantly improved since the introduction of bortezomib, a proteasome inhibitor, and the immunomodulatory drugs (IMiDs) lenalidomide and thalidomide [3]. These drugs have largely improved the rate of complete remission, and significantly increased the time to progression, progression-free survival, and overall survival [4,5].

Of these new agents, thalidomide has been the most widely used drug for the treatment of MM due to its low cost and easy availability. However, it has been reported that the use of thalidomide alone has been linked to an increase in the incidence of VTE by at least 2.1-fold. VTEs increased up to 3.1 times when thalidomide is administrated in combination with high-dose dexamethasone [6]. Incidences of VTE were more frequent during the first 3–6 months of thalidomide treatment [7,8]. Thus, the use of thalidomide-containing regimens should be carefully monitored to prevent thrombosis events [9].

To date, the clinical benefits of single-agent antithrombotic prophylaxis have been reported [10,11]. Although aspirin, warfarin, and low-molecular-weight heparin are all acceptable strategies for antithrombotic prophylaxis, none of them is perfectly reliable. As the primary severe adverse effect (SAE) of anti-thromboembolism is bleeding, and other adverse effects include stomach pain or headache pain, dizziness, and weakness, safety should be addressed for long-term use in MM patients, particularly in elderly patients undergoing chemotherapy [10,11]. Compound Danshen Tablet (CDT), a traditional Chinese herbal preparation, consists of Salvia miltiorrhiza (radix and rhizome of Salvia miltiorrhiza Bge.), accounting for 75% of total phytochemicals, Notoginseng (radix and rhizome of Panax notoginseng) accounting for 24% of chemical constituents, and Borneolum syntheticum (1% of chemical constituents) [12]. CDT has many pharmacological effects, including dilation of coronary arteries, decrease of myocardial oxygen consumption, and improvement of blood viscosity and microcirculation, thus it is widely used to treat cardiovascular disorders [13], atherosclerosis [14], unstable angina pectoris [15], diabetes [16], and diabetic retinopathy [17].

Although many pharmacological activities of CDT have been determined, little is known about its anti-thromboembolic effect in MM patients. In this retrospective study, we evaluated the efficacy and safety of CDT for thromboembolism prevention in MM patients treated with thalidomide-based regimens, based on the patients’ clinical outcomes and the changed D-dimer and fibrinogen levels.

Material and Methods

Study population and data collection

We retrospectively reviewed all of the patients diagnosed with MM and treated with thalidomide-based chemotherapy from January 2008 to March 2015 in the Affiliated Cancer Hospital of Zhengzhou University, The Central Hospital of Xinxiang, and The Second People’s Hospital of Jiaozuo. Patients were excluded from the current retrospective study if they had a history of VTE or existing VTE before treatment, erythropoietin-stimulating factor treatment, less than 2 months of anti-thromboembolism therapy, other malignancies, or blood clotting disorders. Clotting parameters, such as prothrombin time, activated partial thromboplastin time, international normalization ratio, D-dimer, fibrinogen, and whole blood counts, were analyzed. Information regarding the incidence of thrombosis and other AEs was carefully collected in each cohort from initiation of anti-thromboembolism therapy to discontinuation of anti-thromboembolism therapy and chemotherapy. The study protocol for the collection of clinical information was approved by Henan Cancer Hospital Review Board and was conducted according to the Helsinki Declaration.

Administration of thalidomide and anti-thromboembolism therapy

Thalidomide-based chemotherapy regimens consisted of thalidomide (100–200 mg, once before sleep every night) (Changzhou Pharmaceutical Factory, Changzhou, Jiangsu, China) in combination with other chemotherapy regimens. Treatment courses were repeated every 21 days. Patients in the CDT cohort received oral CDT (4 tablets, 3 times a day) (Guangzhou Baihui Pharmaceutical Factory, Changzhou, Jiangsu, China) in combination with other chemotherapy regimens. Treatment courses were repeated every 21 days. Patients in the CDT cohort received oral CDT (4 tablets, 3 times a day) (Guangzhou Baihui Pharmaceutical Factory, Changzhou, Jiangsu, China) in combination with other chemotherapy regimens. Patients in the warfarin cohort were given oral warfarin tablets (Orian Corporation, Espoo, Finland) (1 or 2 mg, once a day) with close monitoring of prothrombin time-international normalized ratio. No other anti-thromboembolic agents were used during the treatment.

Treatment efficacy and safety assessments

The clinical signs and symptoms related to the VTEs in all patients, such as abnormal local swelling, pain, tenderness, temperature, color, or mucosa and hemorheologic indices including
hematocrit and platelet aggregation, were carefully collected. As bleeding is the primary severe adverse effect (AE) of anti-thromboembolism, the clinical signs and symptoms related to bleeding, such as mucosal bleeding, and menstrual blood volume changes for females, were collected. Other adverse effects, including nausea, vomiting, diarrhea, itching, rash, and skin necrosis, were also carefully collected. Adverse events were graded with the use of the Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.

### Statistical analysis

GraphPad Prism 6.0 for Mac was used for statistical analysis. The results are expressed as mean ± standard error of mean (SEM). One-way ANOVA was used for comparisons among 3 groups. Comparisons of variables at the different time points within a group were performed using the paired t test and comparisons of variables between 2 cohorts were performed by using the unpaired t test. VTE incidence rate between 2 cohorts was compared by Fisher’s exact test. All P values were 2-sided. A p < 0.05 was considered statistically significant.

### Results

#### Patient characteristics

A total of 313 MM patients treated with thalidomide-based chemotherapy (130 females and 183 males) were eligible to be evaluated. The median age was 59 years (range 29–76 years). The median treatment duration was 15 months (range 2–45 months). Based on the antithrombotic agents administered, 313 patients were divided into 3 cohorts: CDT cohort (n=130), warfarin cohort (n=94), and no antithrombotic treatment cohort (control group) (n=89). The chemotherapy regimens administered included: melphalan, cyclophosphamide, prednisone, and thalidomide (MPCT) (n=97); vincristine, doxorubicin, dexamethasone, and thalidomide (VADT) (n=93); dexamethasone, thalidomide, cisplatin, Adriamycin, cyclophosphamide, and etoposide (DTPACE) (n=48); or bortezomib, dexamethasone, and thalidomide (BDT) (n=75). The disease status before thalidomide treatment was classified as newly diagnosed or relapsed/refractory MM. A total of 116 MM patients (37.07%) used thalidomide-based regimens as the frontline therapy, while 197 of patients (62.94%) were treated with thalidomide-based regimens while in relapsed/refractory status. Detailed patient characteristics, including immunosuppressive, Durie-Salmon stage, disease status at the beginning of thalidomide treatment, duration of thalidomide use, time from the beginning of thalidomide treatment to the development of a VTE, and regular laboratory data, are summarized in Table 1. No significant differences were found among CDT, warfarin, and control cohorts based on platelet counts, fibrinogen, and D-dimer levels, as well as age, sex, MM type, Durie-Salmon stage, and administration of chemotherapy regimens (Table 2).

#### CDT and warfarin reduce VTE events in the MM patients treated with thalidomide-based regimens

Of the 313 MM patients treated with thalidomide-based regimens, 224 patients (71.57%) had undergone VTE prophylaxis with CDT or warfarin, and none of them developed a VTE. Seven patients (2.24%) developed VTE, all in the no prophylaxis group (i.e., 7 out of 89 patients in the non-prophylaxis group [7.87%] developed VTE). The VTE incidence rate in the control group was significantly higher than that in the CDT and warfarin groups (p=0.002 and p = 0.006, respectively). Among the 7 patients experiencing VTEs, 6 (6.74%) had deep vein thrombosis (DVT) and 1 (1.13%) had pulmonary embolism (PE), which were confirmed by venous ultrasonography and spiral computed tomography, respectively. When VTE was diagnosed, the patient was injected with low-molecular-weight-heparin, either 1 dose daily (1.5 mg/kg/day) or 2 doses daily (1 mg/kg every 12 h). Unfortunately, the patient who developed a PE during the fourth chemotherapy cycle of VADT died. Six patients developing DVT gradually recovered after anti-thromboembolic treatment.

Of 7 VTE cases, 4 were treated with a VADT regimen, 2 were treated with a MCPT regimen, and 1 was treated with BDT regimen. Collectively, 5 of 7 VTE patients (71.43%) received thalidomide plus high-dose dexamethasone therapy, and 4 of 7 VTE patients (57.14%) were treated with thalidomide in combination with high-dose dexamethasone and doxorubicin. According to the Durie-Salmon stage, 6 of 7 VTE patients (85.71%) were diagnosed with stage III (including 5 patients with stage IIIA and 1 with stage IIIB) (Table 3).

#### CDT is better tolerated than warfarin for long-term use in MM patients

Although no VTE occurred in the 2 cohorts with anti-thromboembolism therapy, 3 patients (3.19%) experienced hemorrhage in the warfarin cohort. One experienced gastorrhagia, which was well controlled with iced oral administration of nor-epinephrine, proton pump inhibitors, and transfusion of red blood cells after discontinuation of warfarin treatment; 1 had cerebral hemorrhage, and upon warfarin termination and administering mannitol treatment, the patient improved without neurological sequelae; and 1 experienced retinal hemorrhage and recovered completely after discontinuation of warfarin and administration of CDT 2 weeks later (Table 4). There were no warfarin-associated deaths. In contrast, treatment with CDT was well tolerated, with itching and rash (n=4, grade 1, 2) being the most common AEs. There were also possibly related AEs of palpitations (n=2, grade 1 and 2, respectively) and
headache (n=1, grade 2). These symptoms were relieved after decreasing the dose or intervention with antihistamines in all except 1 patient (grade 3), who suffered from palpitation half an hour after taking CDT and finally stopped the CDT treatment. However, no bleeding and no other SAEs were observed in the CDT cohort.

Table 1. Clinical characteristics and chemotherapy regimens in three cohorts of MM patients.

| Category                      | Control (%) | CDT (%) | Warfarin (%) | Total (%) |
|-------------------------------|-------------|---------|--------------|-----------|
| Total number of patients     | 89 (20.00)  | 130 (46.43) | 94 (33.57) | 313 (100) |
| Age, median, y (range, y)    | 57 (32–76)  | 60 (29–74)  | 59 (34–74)  | 59 (29–76) |
| Disease status (%)           |             |          |              |           |
| New                           | 34 (37.07)  | 47 (36.15)  | 35 (37.23)  | 116 (37.07) |
| R/R                           | 55 (62.93)  | 83 (63.85)  | 59 (62.77)  | 197 (62.94) |
| Gender (%)                    |             |          |              |           |
| Male                          | 53 (59.55)  | 73 (56.15)  | 59 (62.77)  | 185 (59.11) |
| Female                        | 36 (40.45)  | 57 (43.85)  | 35 (37.23)  | 128 (40.89) |
| Classification (%)            |             |          |              |           |
| IgA                           | 23 (25.84)  | 33 (25.38)  | 25 (26.60)  | 81 (25.88)  |
| IgG                           | 51 (57.30)  | 70 (53.85)  | 57 (60.64)  | 178 (56.87) |
| IgM                           | 0 (0.00)    | 3 (2.31)    | 0 (0.00)    | 3 (0.96)    |
| Light chain                   | 15 (16.85)  | 24 (18.46)  | 12 (12.77)  | 51 (16.29)  |
| Durie-Salmon Stage (%)        |             |          |              |           |
| IA                            | 4 (4.49)    | 2 (1.54)    | 2 (2.12)    | 8 (2.56)    |
| IB                            | 0 (0.00)    | 0 (0.00)    | 0 (0.00)    | 0 (0.00)    |
| IIA                           | 29 (32.58)  | 32 (24.62)  | 23 (24.47)  | 84 (26.84)  |
| IIB                           | 4 (4.49)    | 12 (9.23)   | 8 (8.51)    | 24 (7.67)   |
| IIIA                          | 44 (49.44)  | 70 (53.85)  | 50 (53.19)  | 164 (52.40) |
| IIIB                          | 8 (8.99)    | 14 (10.77)  | 11 (11.70)  | 33 (10.54)  |
| Regimen (%)                   |             |          |              |           |
| MPCT                          | 27 (30.34)  | 44 (33.85)  | 26 (27.66)  | 97 (30.99)  |
| DTPACE                         | 15 (16.07)  | 19 (14.62)  | 14 (14.89)  | 48 (15.34)  |
| VADT                          | 25 (28.09)  | 39 (30.00)  | 29 (30.85)  | 93 (29.71)  |
| BDT                           | 22 (24.72)  | 28 (21.54)  | 25 (26.60)  | 75 (23.96)  |

Table 2. Clinical characteristics associated with coagulation before treatment in three cohorts of MM patients.

| Category                | Control (%) | CDT (%) | Warfarin (%) | Total (%) |
|-------------------------|-------------|---------|--------------|-----------|
| D-dimer, mg/L           | 0.361±0.025 | 0.370±0.012 | 0.380±0.020 | 0.621     |
| Fibrinogen, g/L         | 2.49±0.48   | 2.56±0.38 | 2.61±0.45    | 0.255     |
| White blood cell, 10^9/L| 6.0±4.8     | 5.9±2.4   | 5.9±1.9      | 0.358     |
| Hemoglobin, g/L         | 124±13.7    | 134±11.5  | 131±11.4     | 0.174     |
| Platelets, 10^9/L       | 137.5±35.3  | 133.3±44.5 | 137.7±52.7  | 0.483     |
CDT and warfarin reduced the elevated D-dimer and fibrinogen levels induced by thalidomide-based chemotherapy

To evaluate patient coagulation status during thalidomide-based regimens and antithrombotic treatment, D-dimer and fibrinogen levels in the peripheral blood of MM patients were analyzed from pretreatment to 8 months after antithrombotic treatment. We found that D-dimer and fibrinogen levels slightly increased with oral thalidomide in the no prophylaxis cohort. However, the 2 clotting parameters gradually decreased in the CDT and warfarin cohorts. We found no significant differences among the 3 cohorts during the first 2 months of therapy.

After 3 months of thalidomide-based chemotherapy, the mean levels of D-dimer and fibrinogen significantly rose to 0.474 (±0.048) mg/L and 3.26 (±1.53) g/L, respectively, in the control group (n=83) (p=0.002 and p=0.019, respectively), and then slowly increased until 8 months (n=71). Furthermore, the mean D-dimer and fibrinogen levels were 0.79 (±0.163) mg/L and 4.25 (±1.21) g/L, respectively, in MM patients developing VTE, which were significantly higher than that in the no VTE patients receiving thalidomide-based regimens (p<0.0001 and p=0.016, respectively) (Figure 1). Notably, these D-dimer and fibrinogen levels were significantly higher than those in the CDT (n=119) (p=0.001 and p=0.008, respectively) and warfarin cohorts (n=78) (p<0.001 and p=0.007, respectively) until 8 months of observation (Figure 2).

The D-dimer level significantly decreased from 0.380 (±0.020) mg/L at baseline (n=89) to 0.195 (±0.141) mg/L (n=88) in the warfarin cohort (p<0.001) and from 0.370 (±0.012) mg/L at baseline (n=130) to 0.289 (±0.039) mg/L (n=130) in the CDT cohort (p=0.004) after 3 months of antithrombotic treatment, and then remained relatively stable until 8 months after antithrombotic treatment in both groups (all p<0.05) (Figure 2A). In contrast, the fibrinogen level mildly decreased 3 months after treatment of the CDT and warfarin cohorts, and there was no difference between the 2 antithrombotic cohorts. However, the fibrinogen levels continued to decrease 6 months after antithrombotic treatment in the warfarin cohort, which were different from the stable levels in the CDT cohort. The fibrinogen levels significantly decreased from 2.61 (±0.45) g/L at baseline (n=89) to 1.97 (±0.42) g/L 6 months after warfarin treatment (n=81, p=0.013) to 1.54 (±0.78) g/L at 7 months (n=80, p=0.005), and to 1.46 (±0.34) g/L at 8 months (n=78, p=0.0045). The fibrinogen levels in the warfarin cohort were significantly lower than those in the CDT cohort at 7 months (n=122, p=0.006) and at 8 months (n=119, p=0.001) (Figure 2B). Although the fibrinogen levels remained at relatively low levels after 3 months of CDT treatment, no significant differences were found when compared to the baseline levels.

---

**Table 4. Clinical features of 3 patients with hemorrhage resulting from Warfarin.**

| Patient | Sex | Age, y | Stage* | Type | Regimen | Disease status | Weekb | Site of hemorrhage |
|---------|-----|--------|--------|------|---------|----------------|-------|-------------------|
| P1      | M   | 68     | IIIB   | IgG/lambda | VADT   | R/R           | 12    | Gastrorrhagia     |
| P2      | F   | 75     | IIIB   | Kappa   | DTPAGE | R/R           | 16    | Cerebral         |
| P3      | M   | 72     | IIIB   | IgG/kappa | CMPT   | New           | 25    | Retinal           |

* Durie-Salmon; b Duration of warfarin therapy (weeks); c “New” refers to “newly diagnosed”, “R/R” refers to “relapsed/refractory”; d PE, pulmonary embolism, “Y” refers to “yes”, and “N” refers to “no”.

---

**Table 3. Clinical features of 7 patients suffering from VTE.**

| Patient | Sex | Age, y | Stage* | Type | Regimen | Weekb | Disease status | PE* |
|---------|-----|--------|--------|------|---------|-------|----------------|-----|
| P1      | F   | 58     | IIIA   | Lambda | VADT   | 9     | New            | Y   |
| P2      | F   | 49     | IIIB   | IgG/lambda | VADT | 6     | R/R            | N   |
| P3      | M   | 71     | IIIB   | IgG/kappa | CMPT | 10    | New            | N   |
| P4      | M   | 66     | IIIB   | IgA/lambda | VADT | 18    | R/R            | N   |
| P5      | F   | 79     | IIIB   | IgG/kappa | BDT  | 4     | New            | N   |
| P6      | M   | 69     | IIIB   | IgG/kappa | CMPT | 7     | R/R            | N   |
| P7      | F   | 65     | IIIB   | IgA/lambda | VADT | 8     | R/R            | N   |

* Durie-Salmon; b Duration of thalidomide therapy (weeks); c “New” refers to “newly diagnosed”, “R/R” refers to “relapsed/refractory”; d PE, pulmonary embolism, “Y” refers to “yes”, and “N” refers to “no”.

---

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Discussion

In this retrospective study, we found CDT and warfarin could effectively reduce the elevated D-dimer and fibrinogen levels induced by thalidomide-based chemotherapy after 3 months of treatment. More importantly, no patients developed VTE in the CDT cohort, an anti-thromboembolism effect comparable to that of warfarin. No bleeding and other SAEs were also observed, exhibiting its superiority in terms of safety.

Figure 1. D-dimer and fibrinogen levels in the MM patients developing VTE vs. the patients without VTE during thalidomide-based regimens. (A) D-dimer and (B) fibrinogen levels significantly increased in the patients experiencing VTE when compared to the no VTE patients.

Figure 2. Monitoring of D-dimer and fibrinogen levels in MM patients treated with thalidomide-based regimens and anti-thromboembolic agents. (A) D-dimer and (B) fibrinogen levels significantly increased in MM patients with no prophylaxis during thalidomide-based regimens. However, 2 bleeding parameters were obviously decreased 3 months after CDT or warfarin treatment. “m” refers to duration of thalidomide therapy (month), and “0 m” refers to baseline. * p<0.05 compared to baseline level; † p<0.05 compared to the control cohort; ‡ p<0.05 compared to the CDT cohort.
Thalidomide-based regimens have undeniably improved the outcomes of multiple myeloma (MM), but increased the risk of thromboembolic events [6–8]. As shown in this retrospective study, we observed a VTE incidence of 2.24% in all of the patients investigated, and a 7.87% VTE incidence rate in the absence of thalidomide prophylaxis, consistent with previous reports from Asians [18], but lower than the reports from Western countries [19], where VTE incidence was highly variable among the different trials and could be as high as 58% when thalidomide was given in combination with doxorubicin and dexamethasone in the absence of thalidomide prophylaxis [20]. In addition, we also observed that the incidence of VTE events was associated with advanced disease, and combination of thalidomide with high-dose dexamethasone or and doxorubicin, in accord with previous observations [19].

D-dimer, a degradation product of cross-linked fibrin, was repeatedly confirmed to be a highly sensitive and clinically useful marker for predicting thrombosis [24–26]. In this retrospective study, we observed that levels of D-dimer and fibrinogen were significantly increased in the no thalidomide prophylaxis cohort, particularly in those patients who developed VTE, indicating that high levels of D-dimer and fibrinogen are associated with the risk of VTE in MM patients treated with thalidomide-based regimens. Importantly, the administration of CDT could reduce D-dimer and fibrinogen levels, especially the D-dimer levels [23,27]. CDT showed a slowly reducing effect relative to warfarin, which may partially explain the distinct effects of these 2 antithrombotic therapies and the greater safety associated with the use of CDT.

Because the occurrence of thromboembolism may lead to chemotherapy discontinuation and higher health expenditure in MM patients, the risk of thromboembolic events with the use of thalidomide still should not be neglected in Asian populations, although the incidence of VTE events was lower relative to Western countries. Warfarin is the first choice in antithrombotic prophylaxis based on the antithrombotic efficacy and adverse effects of antithrombotic agents. In our retrospective study, 30.03% of patients had undergone VTE prophylaxis with warfarin and none of them experienced VTEs. However, a 3.19% incidence rate of hemorrhage was observed in the warfarin cohort [10,11], which may be associated with poor vascular walls caused by persistent hyperlipidemia and aging in MM patients. In contrast, CDT has been widely used in elderly people in Asian countries, especially in China, because it dilates coronary arteries and improves blood viscosity and microcirculation. In the current retrospective study, 41.53% of patients had undergone VTE prophylaxis with CDT; more interestingly, CDT had a comparable efficacy with warfarin for thromboembolism prophylaxis, but no hemorrhage or other SAEs were found. The possible mechanism by which CDT inhibits thrombosis may be by suppressing the expression of adhesion molecules [21]. Moreover, it was reported that Danshen, the major lipophilic components extracted from Danshen, could have a strong anticoagulant activity by enhancing fibrinolytic activity, decreasing cyclooxygenase-2 activity [22], and inhibiting platelet aggregation [23]. Besides, Asian patients have a much higher incidence of major bleeding [10,18], in contrast to a low incidence of hemorrhage for antithrombotic prophylaxis in Western countries. This fact will undoubtedly affect policy regarding the administration of antithrombotic agents in Asia. Thus, CDT may be a better option for the prevention of thalidomide-associated thromboembolism among MM patients, and will extensively benefit the MM population by virtue of its greater safety and acceptability during long-term use.

Conclusions

These multicenter findings demonstrate that CDT is an effective therapy for the prevention of thalidomide-associated VTE among MM patients based on its clinical outcomes and laboratory prediction marker of thromboembolism risk. Further mechanistic research, rigorously designed pharmacological evaluation, and multicenter clinical trials are warranted.

References:

1. Palumbo A, Anderson K: Multiple myeloma. N Engl J Med, 2011; 364: 1046–60
2. Moreau P, Attal M, Facon T: Frontline therapy of multiple myeloma. Blood, 2014; 125: 3076–84
3. Palumbo A, Rajkumar SV, San Miguel JF et al: International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol, 2014; 32: 587–600
4. Mateos MV, Oriol A, Martinez-Lopez J et al: Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial. Lancet Oncol, 2010; 11: 934–41
5. Benboubker L, Dimopoulos MA, Dispenzieri A et al: Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med, 2014; 371: 906–17
6. El Accaoui RN, Shamsedddeen WA, Taher AT: Thalidomide and thrombosis. A meta-analysis. Thromb Haemost, 2007; 97: 1031–36
7. Uaprasert N, Voorhees PM, Mackman N, Key NS: Venous thromboembolism in multiple myeloma: Current perspectives in pathogenesis. Eur J Cancer, 2010; 46: 1799–99
8. De Stefano V, Za T, Rossi E: Venous thromboembolism in multiple myeloma. Semin Thromb Hemost, 2014; 40: 338–47
9. Lyman GH, Bohle K, Khorana AA et al: Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update 2014. J Clin Oncol, 2015; 33: 654–56
10. Suzuki S, Yamashita T, Kato T et al: Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation. Circ J, 2007; 71: 761–65

11. Bajorek B: A review of the safety of anticoagulants in older people using the medicines management pathway: Weighing the benefits against the risks. Ther Adv Drug Saf, 2011; 2: 45–48

12. Wang G, Wang L, Xiong ZY et al: Compound salvia pellet, a traditional Chinese medicine, for the treatment of chronic stable angina pectoris compared with nitrates: A meta-analysis. Med Sci Monit, 2006; 12(1): SR1–7

13. Xu M, Hao H, Jiang L et al: In vitro inhibitory effects of ethanol extract of Danshen (Salvia miltiorrhiza) and its components on the catalytic activity of soluble epoxide hydrolase. Phytomedicine, 2015; 22: 444–51

14. Gao S, Liu Z, Li H et al: Cardiovascular actions and therapeutic potential of tanshinone IIa. Atherosclerosis, 2012; 220: 3–10

15. Zhang JH, Shang HC, Gao XM et al: Compound Salvia droplet pill, a traditional Chinese medicine, for the treatment of unstable angina pectoris: A systematic review. Med Sci Monit, 2008; 14(1): RA1–7

16. Xie Z, Loi Truong T, Zhang P et al: Dan-Qi prescription ameliorates insulin resistance through overall corrective regulation of glucose and fat metabolism. J Ethnopharmacol, 2015; 172: 70–79

17. Lian F, Wu L, Tian J et al: The effectiveness and safety of a danshen-containing Chinese herbal medicine for diabetic retinopathy: A randomized, double-blind, placebo-controlled multicenter clinical trial. J Ethnopharmacol, 2015; 164: 71–77

18. Wu SY, Yeh YM, Chen YP et al: Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan. Ann Hematol, 2012; 91: 1773–78

19. Cini M, Zamagni E, Valdré L et al: Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: Thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin. Eur J Haematol, 2010; 84: 484–92

20. Baz R, Li L, Kottke-Marchant K et al: The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc, 2005; 80: 1568–74

21. Spelman K, Aldag R, Hamman A et al: Traditional herbal remedies that influence cell adhesion molecule activity. Phytother Res, 2011; 25: 473–83

22. Wang C, Li X, Meng X et al: Prevention of experimental postsurgical peritoneal adhesions through the intraperitoneal administration of tanshinone IIa. Planta Med, 2014; 80: 969–73

23. Malone F, De Feo V, Calazzo E et al: Tanshinone IIa, a major component of Salvia miltiorrhiza Bunge, inhibits platelet activation via Erk-2 signaling pathway. J Ethnopharmacol, 2014; 155: 1236–42

24. Ay C, Vormittag R, Dunkler D et al: D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: Results from the Vienna Cancer and Thrombosis Study. J Clin Oncol, 2009; 27: 4124–29

25. van Hylckama Vlieg A, Baglin CA, Luddington R et al: The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: Results of the THE-VTE study. J Thromb Haemost, 2015; 13: 1642–52

26. Kovacs MI, Davies GA, Chapman JA et al: Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: Effect on thrombin generation and procoagulant markers in NCIC CTG MY.10. Br J Haematol, 2015; 168: 511–17

27. Sun M, Zhang JL, Shan JZ et al: Clinical observation of Danhong Injection (herbal TCM product from Radix Salviae miltiorrhizae and Flos Carthami tinctorii) in the treatment of traumatic intracranial hematoma. Phytomedicine, 2009; 16: 683–89